Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04240405
Other study ID # 69HCL19-0373
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 11, 2019
Est. completion date February 11, 2024

Study information

Verified date December 2023
Source Hospices Civils de Lyon
Contact Marie-Helene COSTE, PR
Phone 4 72 43 20 76
Email marie-helene.coste@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Episodic Specificity Induction (ESI) is a short training that improves the production of episodic details during autobiographical recall in young and elderly people without cognitive impairment. But it remains to be determined 1) whether the mechanisms targeted by the ESI affect memory or executive functioning and 2) whether amnestic type (aMCI) or dysexecutive type (dMCI) mild cognitive impairment patients would benefit differently from this training, which has never been tested. By comparing the effect of the ESI on these patients, this would open up new perspectives for their symptomatic care.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date February 11, 2024
Est. primary completion date February 11, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria: The participant: - has provided informed consent obtained in accordance with Good Clinical Practices. - is affiliated to a social security system. - speaks fluent French. - is between 55 and 85 years of age. For the participants of the control group: - has a Montreal Cognitive Assessment (MoCA) score equal to or greater than 26; - has neuropsychological assessment performance (RL/RI 16, D080, TMT, VOSP, Rey's figure) in the norm according to his socio-professional category and age, i.e. less than two deviating scores of -1 standard deviation or less than the 10th percentile per function. For patients in the TCLa group: - has at least two scores below the 10th percentile or below -1 standard deviation from the norm on neuropsychological assessment tests that assess memory, based on its socio-professional category and age; - has less than two scores below the 10th percentile or less than -1 standard deviation from the norm in neuropsychological assessment tests that assess other functions. This is in accordance with the diagnostic criteria of Petersen (2004) and Jak and Bondi (2009). For patients in the TCLd group: - has focal executive dysfunction expressed by at least two scores less than the 10th percentile or less than -1 standard deviation from the norm in neuropsychological assessment tests that assess executive functions (TMT, Stroop, verbal fluences, free recall in memory), according to his socio-professional category and age; - has less than two scores below the 10th percentile or less than -1 standard deviation from the norm on neuropsychological assessment tests that assess other functions (except for free memory reminders and language fluences). This is in accordance with the diagnostic criteria of Petersen (2004) and Jak and Bondi (2009). Exclusion Criteria: The participant: - meets the criteria for a major neurocognitive disorder of the DSM-5. - has a neurological disorder of infectious origin. - has a psychiatric illness. - has a severe uncompensated sensory deficit. - is a substance abuser. - has had chronic depression or anxiety that has not stabilized for 3 months. - refuses to participate. - is participating in another intervention research project. - is placed under the protection of justice. - refuses to sign the consent form. - is unable to express its consent. - consumed toxic substances or alcohol at the time of the study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Laboratoire d'Étude des Mécanismes Cognitifs Bron
France Centre Mémoire Ressources Recherche de Lyon, Institut du Vieillissement, Hôpital des Charpennes Villeurbanne

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average number of internal details The participant sees 5 images evoking various events (e.g., a birthday, a restaurant) and describes for each one a related memory for 3 minutes. Each verbal production is recorded with a dictaphone, transcribed and then segmented into internal (episodic) or external (non-episodic) details according the coding procedure of Levine et al. (2002). The average number of internal details by autobiographical recall task is then calculated from these data. Day 0 (at inclusion)
See also
  Status Clinical Trial Phase
Recruiting NCT05754567 - CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Not yet recruiting NCT03276377 - VItamin K Inhibition and NeurocoGnition (VIKING) N/A
Completed NCT04175223 - Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Recruiting NCT05732285 - A Pilot Randomized Controlled Trial: CoINTEGRATE N/A
Recruiting NCT04095962 - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia N/A
Not yet recruiting NCT04113577 - COgilus Remediation in Alzheimer Patients (CORA)
Recruiting NCT06320639 - DRIVing Simulator and People With NeuroCognitive Disorders
Recruiting NCT06105320 - COGNIFOOD-Changing the Carbohydrate/Fat-ratio to Prevent Cognitive Decline and Alzheimer Pathology: A Pilot Study N/A
Completed NCT03050385 - Cognitive Rehabilitation During Transcranial Direct Current Stimulation N/A
Active, not recruiting NCT06372002 - Effectiveness and Cost-Effectiveness of Cognitive Stimulation Therapy - Spain (CST-ES) in People Living With Dementia N/A
Recruiting NCT05508789 - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Phase 3
Recruiting NCT03926351 - High Dose Omega 3 in People at Risk for Dementia Phase 2
Recruiting NCT05504681 - Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
Completed NCT04168268 - Patient-reported Outcome Measures After Post-anesthesia Care Unit Delirium
Recruiting NCT04825847 - Neurocognitive Disorders After Major Surgery in Elderly N/A
Active, not recruiting NCT02958670 - Imaging Tau Deposition in the Brain of Elderly Subjects N/A
Enrolling by invitation NCT02652598 - Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD Phase 2
Completed NCT02825732 - MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint N/A